• Conditions and diseases

  • Blood and immune system •
  • Cancer •
  • Cardiovascular •
  • Central nervous system •
  • Digestive system •
  • Ear and nose •
  • Endocrine, nutritional and metabolic •
  • Eye •
  • Gynaecology, pregnancy and birth •
  • Infectious diseases •
  • Injuries, accidents and wounds •
  • Mental health and behavioural conditions •
  • Mouth and dental •
  • Musculoskeletal •
  • Respiratory •
  • Skin •
  • Urogenital

• Public health

  • Accidents and injuries •
  • Alcohol •
  • Behaviour change •
  • Cancer •
  • Cardiovascular disease •
  • Child health •
  • Child social care •
  • Chronic illness •
  • Diabetes •
  • Drugs •
  • Environmental health •
  • Infectious diseases •
  • Maternal health •
  • Mental health •
  • Non-communicable diseases •
  • Obesity and diet •
  • Occupational health •
  • Older people •
  • Physical activity •
  • Sexual health •
  • Smoking and tobacco •
  • Transport •
  • Vaccine preventable diseases •
  • Working with and involving communities

• Treatments, Procedures and Devices

  • Bones and joint surgery •
  • Cardiovascular surgery •
  • Cardiovascular system drug treatments •
  • Clinical devices •
  • Diagnostic imaging •
  • Diagnostic procedures •
  • Digestive tract and other abdominal organs surgery •
  • Drug treatments •
  • Endocrine system and breast surgery •
  • Eye surgery •
  • Nervous system surgery •
  • Radiotherapy •
  • Screening •
  • Surgical procedures •
  • Therapeutic procedures •
  • Tissue and organ donation •
  • Urogenital surgery

• Guidance by type

  • Clinical Guidelines •
  • Technology appraisals •
  • Public health guidance •
  • Diagnostics guidance •
  • Interventional procedures guidance •
  • Medical technologies guidance •
  • Cancer service guidance •
  • Quality standards

• Guidance by date

  • View the guidance by date published

About NICE guidance Close

Navigation

• NICE guidance

• Find guidance
• NICE Pathways
• Latest guidance
• Guidance by type
• Guidance in development
• How guidance is produced
• NICE guidance research recommendations
• Guidance for patients and public
• Other publications
• Patient safety solutions pilot
• Quality standards

Vascular disease - clopidogrel and dipyridamole (review) [ID32]

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90)

Status:	In progress
Expected date of issue:	December 2010
Wave:	R
Process:	MTA
Topic area: Cardiovascular

Project team | Schedule | Stakeholders | Project history | Key documents

 

NICE project team

Executive Lead:	Gillian Leng
Technical Lead:	Panagiota Vrouchou and Helen Starkie
Communications manager:	Phil Ranson
Project manager:	Lori Farrar
Assessment group:	Liverpool Reviews and Implementation Group

Top

 

Provisional schedule

Closing date for invited submissions / evidence submission:	16 October 2009
1st appraisal committee meeting:	08 July 2010
2nd appraisal committee meeting:	08 September 2010

Top

 

Consultees and commentators

Consultees Commentators (no right to submit or appeal) Manufacturers / Sponsors Beacon Pharmaceuticals (clopidogrel) Boehringer-Ingelheim (dipyridamole) Bristol-Myers Squibb Pharmaceuticals and Sanofi-Aventis [joint marketing authorisation] (clopidogrel) Consilient (clopidogrel) Patient / Carer Groups Anticoagulation Europe (ACE) Diabetes UK HEART UK Heart Care Partnership Insulin Dependent Diabetes Trust (IDDT) Stroke Association Professional groups Association of British Neurologists British Association of Stroke Physicians British Cardiovascular Society British Cardiovascular Intervention Society (BCIS) British Heart Foundation Royal College of Nursing Royal College of Physicians Cardiology Committee Vascular Society Others Department of Health Welsh Assembly Government General Commissioning Support Appraisals Service Department of Health, Social Services and Public Safety for Northern Ireland Medicines and Healthcare products Regulatory Agency NHS Quality Improvement Scotland Possible comparator manufacturer(s) Bayer (aspirin) Galpharm-International (aspirin) Relevant research groups None Assessment Group Liverpool Reviews & Implementation Group, University of Liverpool National Institute for Health Research Health Technology Assessment Programme Associated Guideline Groups None Associated Public Health Groups None

Top

 

Project history

Date Update 1st April 2010 The first  Appraisal Committee meeting  will now take place on Thursday 8th July 2010.  The reason for the timing change is to allow time for additional data collection, model development and analysis for inclusion in the Assessment report and is in line with NICE processes.

Top

 

Key documents

Vascular disease - clopidogrel and dipyridamole (review): equality impact assessment 14 January 2011 Vascular disease - clopidogrel and dipyridamole (review): press release 21 October 2010 Vascular disease - clopidogrel and dipyridamole (review): final appraisal determination 21 October 2010 Vascular disease - clopidogrel and dipyridamole (review): appraisal consultation 04 August 2010 Vascular disease - clopidogrel and dipyridamole (review): addendum to assessment report 25 May 2010 Vascular disease - clopidogrel and dipyridamole (review): assessment report 21 May 2010 Vascular disease - clopidogrel and dipyridamole (review): final protocol 21 January 2010 Vascular disease - clopidogrel and dipyridamole: Institute's response to comments on the draft matrix 09 July 2009 Vascular disease - clopidogrel and dipyridamole: Institute's response to comments on the draft scope 09 July 2009 Vascular disease - clopidogrel and dipyridamole: final scope 09 July 2009 Vascular disease - clopidogrel and dipyridamole: provisional matrix 28 May 2009 Vascular disease - clopidogrel and dipyridamole: draft scope 28 May 2009

This page was last updated: 28 February 2012